Icahn School of Medicine at Mount Sinai Names Miriam Merad, MD, PhD, as Dean for Translational Research and Therapeutic Innovation

Miriam Merad, MD, PhD, a world-renowned immunologist, has been appointed Dean for Translational Research and Therapeutic Innovation of the Icahn School of Medicine at Mount Sinai. The appointment reaffirms Icahn Mount Sinai’s commitment to pioneering medical progress and catalyzing the rapid advancement of research innovation. Dr. Merad, the Mount Sinai Professor in Cancer Immunology, will also continue to serve as the founding Chair of the Department of Immunology and Immunotherapy, Director of the Marc and Jennifer Lipschultz Precision Immunology Institute, and Director of the Human Immune Monitoring Center.
As Dean, Dr. Merad aims to elevate early clinical trials at Icahn Mount Sinai, streamline the clinical trial process, cultivate a culture of mechanistic clinical trials throughout the campus, and forge stronger partnerships with the pharmaceutical and biotech sectors.

UNLV Immunologist on the Differences Between Two Leading COVID-19 Vaccine Candidates

Millions around the world have waited for news about a COVID-19 vaccine, regarding it as the beginning of the end for the global pandemic and a herald for the eventual return to “normal life.” Recent announcements from pharmaceutical companies Pfizer and Moderna that their respective late-stage vaccine trials have shown a 90% or better effectiveness rate have received international applause, excitement furthered with estimates that doses could be ready as early as December.